This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Udelson, J. E. Search for Related Content PubMed PubMed Citation Articles by Udelson, J. E. Related Collections Other heart failure

Editorials

The Inaugural Issue of Circulation: Heart Failure

James E. Udelson, MD

From the Tufts Medical Center, Division of Cardiology, Boston, Mass.

Correspondence to James E. Udelson, MD, Tufts Medical Center, Division of Cardiology, 750 Washington St, Box 70, Boston, MA 02111. E-mail judelson@tuftsmedicalcenter.org

Key Words: Editorials • heart failure • research • publishing

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Welcome to the new journal Circulation: Heart Failure. Following Circulation: Arrhythmia and Electrophysiology, it is one of the first of 6 Circulation subspecialty journals to be published.

Knowledge in the field of heart failure has grown substantially over recent years, as has the breadth of research, paralleling the growth of the clinical problem. Because of better survival rates after myocardial infarction and the aging of the general population, heart failure has occupied and will likely continue to occupy a greater share of clinicians’ focus over time. The array of potential therapies has expanded, and the coming years will likely see the emergence of new advances in devices and regenerative therapies and more focused therapies based on pharmacogenomics as our vision expands beyond broadly based pharmacological therapies. Transplantation and its accompanying therapies, as well as ventricular assist and ventricular replacement, are fields that continue to push boundaries.

Given this explosion of information and nascent knowledge, the time seemed right for a journal devoted to exploring and highlighting many of those advances. At the manuscript review meetings for Circulation, we found ourselves commonly having to reject quality manuscripts simply on the basis of priority or because the work had a focus that was felt to be too highly subspecialized in nature. Such manuscripts will now have a potential home in Circulation: Heart Failure.

The journal will publish high-quality and rigorously executed investigations in the fields of clinical science and translational science, as well as basic research articles that . . . [Full Text of this Article]

This article has been cited by other articles:

				S. D. Solomon, E. Appelbaum, W. J. Manning, A. Verma, T. Berglund, V. Lukashevich, C. Cherif Papst, B. A. Smith, B. Dahlof, and for the Aliskiren in Left Ventricular Hypertrophy Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy Circulation, February 3, 2009; 119(4): 530 - 537. [Abstract] [Full Text] [PDF]